MX2019004096A - Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion. - Google Patents
Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion.Info
- Publication number
- MX2019004096A MX2019004096A MX2019004096A MX2019004096A MX2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A MX 2019004096 A MX2019004096 A MX 2019004096A
- Authority
- MX
- Mexico
- Prior art keywords
- leukotriene
- neuroinflammation
- safe
- effective amount
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un dispositivo y método para tratar una enfermedad o condición neurodegenerativa asociada con neuroinflamacion inducida por un leucotrieno; el dispositivo es una forma de dosificación unitaria de película que tiene una capa de película y una cantidad segura y efectiva de un inhibidor de la síntesis de leucotrienos o antagonista del receptor de leucotrienos; el dispositivo esta configurado y formulado para lograr el suministro transmucoso y/o enteral del inhibidor de la síntesis de leucotrienos o antagonista del receptor de leucotrienos; el método incluye suministrar por vía transmucosa y/o enteral a un animal en necesidad de tratamiento, una cantidad segura y efectiva de un bloqueador de leucotrienos capaz de cruzar la barrera hemoencefalica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/299,054 US9949934B1 (en) | 2016-10-20 | 2016-10-20 | Device and method of treating conditions associated with neuroinflammation |
PCT/CA2017/051231 WO2018072015A1 (en) | 2016-10-20 | 2017-10-17 | Device and method of treating conditions associated with neuroinflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019004096A true MX2019004096A (es) | 2019-09-26 |
Family
ID=61952387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019004096A MX2019004096A (es) | 2016-10-20 | 2017-10-17 | Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion. |
Country Status (10)
Country | Link |
---|---|
US (3) | US9949934B1 (es) |
EP (1) | EP3528796B1 (es) |
JP (1) | JP2019531310A (es) |
KR (1) | KR20190071692A (es) |
CN (1) | CN109843273A (es) |
AU (1) | AU2017344764A1 (es) |
BR (1) | BR112019007321A2 (es) |
CA (2) | CA2998218C (es) |
MX (1) | MX2019004096A (es) |
WO (1) | WO2018072015A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3562486T3 (da) | 2016-12-31 | 2024-06-10 | Bioxcel Therapeutics Inc | Anvendelse af sublingual dexmedetomidin til behandling af agitation |
CN112888431B (zh) | 2018-06-27 | 2022-06-03 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
AU2019334202A1 (en) | 2018-09-06 | 2021-03-25 | Innopharmascreen, Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
WO2020051709A1 (en) * | 2018-09-14 | 2020-03-19 | Intelgenx Corp. | Method of treatment and device for the improved bio availability of montelukast, a leukotriene receptor antagonist |
US11602504B2 (en) | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
US20240024288A1 (en) | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5857296A (en) | 1995-05-17 | 1996-11-29 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
WO1999040898A2 (en) * | 1998-02-12 | 1999-08-19 | Centrapharm Inc. | Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect |
US8575194B1 (en) | 2004-08-31 | 2013-11-05 | Jack William Schultz | Treatment methods of cognitive, emotional and mental ailments and disorders |
US9149472B2 (en) | 2004-08-31 | 2015-10-06 | Jack William Schultz | Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders |
KR101074271B1 (ko) * | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
KR101077468B1 (ko) * | 2011-03-04 | 2011-11-07 | (주)차바이오앤디오스텍 | 안정한 경구용 속용 필름 제제 |
KR20130074766A (ko) * | 2011-12-26 | 2013-07-04 | 에스케이케미칼주식회사 | 몬테루카스트 또는 이의 약학적으로 허용 가능한 염을 포함한 구강투여용 필름 |
JP5841433B2 (ja) * | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | 口腔内フィルム状基剤及び製剤 |
US20150322049A1 (en) * | 2012-12-13 | 2015-11-12 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
EP3102209B1 (en) | 2014-02-04 | 2021-04-07 | Bioscience Pharma Partners, LLC | Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system |
CN104784157B (zh) * | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
US20170258710A1 (en) * | 2016-03-11 | 2017-09-14 | Intelgenx Corp. | Montelukast transmucosal film |
-
2016
- 2016-10-20 US US15/299,054 patent/US9949934B1/en active Active
-
2017
- 2017-10-17 CN CN201780062591.7A patent/CN109843273A/zh active Pending
- 2017-10-17 CA CA2998218A patent/CA2998218C/en active Active
- 2017-10-17 WO PCT/CA2017/051231 patent/WO2018072015A1/en unknown
- 2017-10-17 JP JP2019519008A patent/JP2019531310A/ja active Pending
- 2017-10-17 KR KR1020197010090A patent/KR20190071692A/ko unknown
- 2017-10-17 MX MX2019004096A patent/MX2019004096A/es unknown
- 2017-10-17 BR BR112019007321A patent/BR112019007321A2/pt not_active Application Discontinuation
- 2017-10-17 CA CA3122192A patent/CA3122192A1/en active Pending
- 2017-10-17 AU AU2017344764A patent/AU2017344764A1/en not_active Abandoned
- 2017-10-17 EP EP17862398.9A patent/EP3528796B1/en active Active
-
2018
- 2018-03-05 US US15/912,103 patent/US10722476B2/en active Active
-
2019
- 2019-06-14 US US16/441,872 patent/US20190290595A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2998218C (en) | 2021-06-15 |
BR112019007321A2 (pt) | 2019-07-02 |
JP2019531310A (ja) | 2019-10-31 |
KR20190071692A (ko) | 2019-06-24 |
EP3528796A1 (en) | 2019-08-28 |
US20180228738A1 (en) | 2018-08-16 |
EP3528796B1 (en) | 2024-02-07 |
US20180110738A1 (en) | 2018-04-26 |
WO2018072015A1 (en) | 2018-04-26 |
EP3528796A4 (en) | 2020-04-29 |
CN109843273A (zh) | 2019-06-04 |
CA3122192A1 (en) | 2018-04-20 |
CA2998218A1 (en) | 2018-04-20 |
US9949934B1 (en) | 2018-04-24 |
AU2017344764A1 (en) | 2019-05-02 |
US20190290595A1 (en) | 2019-09-26 |
US10722476B2 (en) | 2020-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019004096A (es) | Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion. | |
GB2538682A (en) | Nasal drug products and methods of their use | |
ES2675779T3 (es) | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R | |
BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
MX2016016744A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2019010573A (es) | Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno. | |
CL2015001923A1 (es) | Uso de crenolanib para el tratamiento de trastornos proliferativos que tiene flt3 mutado | |
CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
PH12016502353A1 (en) | Pharmaceutical composition | |
MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
CL2015002847A1 (es) | Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015). | |
EA201690874A1 (ru) | Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением | |
BR112017017729A2 (pt) | forma de dosagem oral de liberação controlada de agonista de receptor gaba | |
AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
CL2016000325A1 (es) | Antagonistas de vía para tratar trastornos del sueño por cambio de fase | |
PH12016500666A1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
CY1118532T1 (el) | Φαρμακευτικη συνθεση για χρηση στη θεραπευτικη αγωγη ή προληψη των ελλειψεων βιταμινων και μεταλλικων αλατων σε ασθενεις που εχουν υποβληθει σε επεμβαση γαστρικης παρακαμψης | |
AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. |